PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26023F0028TYVASO — Actelion Pharmaceuticals Us Inc

Actelion Pharmaceuticals Us Inc holds $5.4M across 106 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 1 related award under parent 36F79719D0142. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Sep 30, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

260-Network Contract Office 20 (36C260)

Awarding office

Actelion Pharmaceuticals Us Inc

Recipient

Sep 30, 2023

PoP end

$176K

Obligated

$176K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Actelion Pharmaceuticals Us Inc — $90

Contract facts

Federal

Contract number36C26023F0028

Also listed as36C260-23-F-0028

Also listed as36F79719D0142-36C26023F0028

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentActelion Pharmaceuticals Us Inc

CAGE33TN9

UEIH5BMHLMMNA28

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79719D0142

Place of performanceSILVER SPRING MD

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startOct 1, 2022

PoP end (current)Sep 30, 2023

Obligated$176K

Current value$176K

Potential value$176K

TYVASO is a federal award for 260-Network Contract Office 20 (36C260) held by Actelion Pharmaceuticals Us Inc. Estimated value $176K ($176K obligated). Current period of performance ends Sep 30, 2023. Last award drew 1 bidder. Place of performance: SILVER SPRING MD.

Recompete timing

Public

● Past PoP end (1056 days ago)

Current PoP ended Sep 30, 2023 (1056 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Actelion Pharmaceuticals Us Inc — $5.4M obligated across 106 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($5.4M) · all agencies

Department of Veterans Affairs (VA)$3.2M · 59%Department of Justice (DOJ)$2.2M · 41%

Open full company profile →

Related awards

Same parent · incumbent

36C26026F0017

UPTRAVI 800MCG TABS

$407K

Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26023F0028?

36C26023F0028 (TYVASO) is a 260-Network Contract Office 20 (36C260) award with a potential value of $176K, currently held by Actelion Pharmaceuticals Us Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-23-F-0028?

36C260-23-F-0028 is the dashed form of PIID 36C26023F0028 (TYVASO), held by Actelion Pharmaceuticals Us Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26023F0028?

260-Network Contract Office 20 (36C260) awarded 36C26023F0028 to Actelion Pharmaceuticals Us Inc (potential $176K).

Who is the incumbent on 36C26023F0028?

Actelion Pharmaceuticals Us Inc is the incumbent with $5.4M across 106 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2023.

When does Actelion Pharmaceuticals Us Inc’s 36C26023F0028 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Oct 1, 2022